Effects of Electronic Cigarettes in Cigarette Smokers With Mild to Moderate COPD
NCT ID: NCT03379025
Last Updated: 2019-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2019-10-31
2021-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metered Cryospray for the Treatment of Patients With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
NCT03892694
An Educational Intervention to Improve Disease Management Knowledge of Hospitalized Patients With COPD
NCT03323190
Randomized Controlled Trial of Exercise Training in Patients With COPD
NCT00012792
A Mobile Integrated Health Intervention to Manage Congestive Health Failure and Chronic Obstructive Pulmonary Disease
NCT05540158
Safety of Anti-Depressant for Chronic Obstructive Pulmonary Disease (SAD-COPD)
NCT02813447
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It is important to understand how electronic cigarettes affects symptoms and lung function in smokers with COPD to determine the short-term safety of these products. To do this, an initial step involves observing the extent to which smokers substitute their conventional cigarette use with electronic cigarette use and change their exposure to tobacco use biomarkers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Early Intervention Group
JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks
Electronic cigarette
electronic cigarette and cartridge refills (also known as pods)
Delayed Intervention Group
After a 12 week period of no electronic cigarette use, JUUL Electronic Cigarettes, nicotine concentration 59 mg/ml, to replace all cigarette use for 12 weeks
Electronic cigarette
electronic cigarette and cartridge refills (also known as pods)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Electronic cigarette
electronic cigarette and cartridge refills (also known as pods)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Daily use of at least 5 cigarettes
* No plan to quit cigarettes in the next 30 days
* Willing to use e-cigarettes
* Diagnosis of COPD (FEV1/forced vital capacity \[FVC\] \<0.70) with mild (FEV1 \>80% predicted) or moderate (FEV1 \<80% but \>50% predicted) airflow limitation (post-bronchodilator); confirmed by spirometry
* English-speaking
Exclusion Criteria
* Past 30 day use of inhaled drugs (marijuana, crack)
* Pregnant or breastfeeding
* Planning to become pregnant within the next 3 months or unable to agree to use appropriate contraception during study
* Pulmonary disease other than COPD or asthma
* Ever requiring mechanical ventilation
* 2 or more hospitalizations for COPD in the past 12 months
* Cardiac hospitalization in the past 6 months
* Active chest pain or palpitations
* Uncontrolled hypertension (blood pressure \>160/100)
* Oxygen therapy
* Inability or contraindication to perform spirometry (e.g. recent eye, thoracic, or abdominal surgery)
* Known allergy to propylene glycol or vegetable glycerin
* Unable to consent or complete assessments
40 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sara Kalkhoran
Assistant Professor of Medicine
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017P002418
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.